Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 137240
Corporate User License Price USD 6000
Corporate User License Price INR 411720
Site License Price USD 4000
Site License Price INR 274480
Request a Quote

Report Title

candidiasis-pipeline review, h2 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

candidiasis-pipeline review, h2 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

candidiasis-pipeline review, h2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

candidiasis-pipeline review, h2 2017



Executive Summary

Candidiasis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis-Pipeline Review, H2 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 7, 2, 22, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively.

Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).

-The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Candidiasis-Overview 7

Candidiasis-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Candidiasis-Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Candidiasis-Companies Involved in Therapeutics Development 25

Amplyx Pharmaceuticals Inc 25

Bakker Medical Srl 25

Beta Pharma Inc 26

Biomar Microbial Technologies 26

Bionex Pharmaceuticals LLC 27

Biosergen AS 27

Cidara Therapeutics Inc 28

Dermala Inc 28

Gedea Biotech AB 29

General Biologicals Corp 29

Grupo Ferrer Internacional SA 30

Hsiri Therapeutics LLC 30

iCo Therapeutics Inc. 31

ImmunoClin Corp 31

Matinas BioPharma Holdings Inc 32

Nanomerics Ltd 32

Novabiotics Ltd 33

NovaDigm Therapeutics Inc 33

Novartis AG 34

Onxeo SA 34

Scynexis Inc 35

Sealife PHARMA GMBH 35

Viamet Pharmaceuticals Inc 36

Visterra Inc 36

Wellstat Vaccines LLC 37

Candidiasis-Drug Profiles 38

(clotrimazole + diclofenac sodium)-Drug Profile 38

61894700-Drug Profile 39

AC-17-Drug Profile 40

amphotericin B-Drug Profile 41

amphotericin B-Drug Profile 43

amphotericin B-Drug Profile 49

Amphotericin B sodium-Drug Profile 50

Antibody to Target Ece1 for Candidiasis-Drug Profile 52

APX-001-Drug Profile 53

APX-001A-Drug Profile 55

arasertaconazole-Drug Profile 56

B-4010-Drug Profile 57

BL-5923-Drug Profile 58

BSG-005-Drug Profile 59

candidiasis vaccine-Drug Profile 60

CD-101-Drug Profile 61

Cellullar Immunotherapy for Viral Infections and Fungal Infections-Drug Profile 66

CLX-159-Drug Profile 67

CSA-13-Drug Profile 68

Drug for Candidiasis-Drug Profile 70

Drug for Oral Candidiasis-Drug Profile 71

Forazoline A-Drug Profile 72

GA-101-Drug Profile 73

iCo-010-Drug Profile 74

interleukin-22-Drug Profile 75

JSM-11-Drug Profile 76

KSL-W-Drug Profile 77

miconazole nitrate-Drug Profile 78

Monoclonal Antibodies for Candidiasis-Drug Profile 80

Monoclonal Antibody for Candidiasis-Drug Profile 81

Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections-Drug Profile 82

mutanobactin A-Drug Profile 83

NDV-3-Drug Profile 84

NDV-3A-Drug Profile 86

NP-339-Drug Profile 88

obliquumol-Drug Profile 89

Occidiofungin-Drug Profile 90

P-113Du-Drug Profile 91

P-113Tri-Drug Profile 92

PAC-113-Drug Profile 93

Polymers for Clostridium difficile Infections and Candidiasis-Drug Profile 95

Prof-002-Drug Profile 96

Recombinant Enzyme for Candidiasis-Drug Profile 97

Recombinant Peptides for Oropharyngeal Candidiasis-Drug Profile 98

SCY-078-Drug Profile 99

SLP-0901-Drug Profile 107

SLP-0904-Drug Profile 108

Small Molecule for Bacterial Vaginosis and Candidiasis-Drug Profile 109

Small Molecule for Candidiasis-Drug Profile 110

Small Molecule for Fungal Infections-Drug Profile 111

Small Molecules for Aspergillosis and Candidiasis-Drug Profile 112

Small Molecules for Candidiasis-Drug Profile 113

Small Molecules for Candidiasis-Drug Profile 114

Small Molecules for Candidiasis-Drug Profile 115

Small Molecules for Fungal Infections-Drug Profile 116

Small Molecules for Fungal Infections-Drug Profile 117

Small Molecules for Systemic Candidiasis-Drug Profile 118

Synthetic Peptide to Inhibit CBL-B for Candidiasis-Drug Profile 119

Synthetic Peptides for Candidiasis-Drug Profile 120

Synthetic Peptides for Infections Diseases and Oncology-Drug Profile 121

TOL-463-Drug Profile 122

Vaccine to Target Ece1 for Candidiasis-Drug Profile 123

Vaccine to Target Glucosylceramide for Fungal Infections-Drug Profile 124

VIS-FNG-Drug Profile 125

voriconazole-Drug Profile 126

VT-1129-Drug Profile 127

VT-1161-Drug Profile 129

VT-1598-Drug Profile 136

Candidiasis-Dormant Projects 138

Candidiasis-Discontinued Products 141

Candidiasis-Product Development Milestones 142

Featured News & Press Releases 142

Appendix 155

Methodology 155

Coverage 155

Secondary Research 155

Primary Research 155

Expert Panel Validation 155

Contact Us 155

Disclaimer 156

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Candidiasis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

List of Tables

Number of Products under Development for Candidiasis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Candidiasis-Pipeline by Amplyx Pharmaceuticals Inc, H2 2017

Candidiasis-Pipeline by Bakker Medical Srl, H2 2017

Candidiasis-Pipeline by Beta Pharma Inc, H2 2017

Candidiasis-Pipeline by Biomar Microbial Technologies, H2 2017

Candidiasis-Pipeline by Bionex Pharmaceuticals LLC, H2 2017

Candidiasis-Pipeline by Biosergen AS, H2 2017

Candidiasis-Pipeline by Cidara Therapeutics Inc, H2 2017

Candidiasis-Pipeline by Dermala Inc, H2 2017

Candidiasis-Pipeline by Gedea Biotech AB, H2 2017

Candidiasis-Pipeline by General Biologicals Corp, H2 2017

Candidiasis-Pipeline by Grupo Ferrer Internacional SA, H2 2017

Candidiasis-Pipeline by Hsiri Therapeutics LLC, H2 2017

Candidiasis-Pipeline by iCo Therapeutics Inc., H2 2017

Candidiasis-Pipeline by ImmunoClin Corp, H2 2017

Candidiasis-Pipeline by Matinas BioPharma Holdings Inc, H2 2017

Candidiasis-Pipeline by Nanomerics Ltd, H2 2017

Candidiasis-Pipeline by Novabiotics Ltd, H2 2017

Candidiasis-Pipeline by NovaDigm Therapeutics Inc, H2 2017

Candidiasis-Pipeline by Novartis AG, H2 2017

Candidiasis-Pipeline by Onxeo SA, H2 2017

Candidiasis-Pipeline by Scynexis Inc, H2 2017

Candidiasis-Pipeline by Sealife PHARMA GMBH, H2 2017

Candidiasis-Pipeline by Viamet Pharmaceuticals Inc, H2 2017

Candidiasis-Pipeline by Visterra Inc, H2 2017

Candidiasis-Pipeline by Wellstat Vaccines LLC, H2 2017

Candidiasis-Dormant Projects, H2 2017

Candidiasis-Dormant Projects, H2 2017 (Contd..1), H2 2017

Candidiasis-Dormant Projects, H2 2017 (Contd..2), H2 2017

Candidiasis-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Amplyx Pharmaceuticals Inc

Bakker Medical Srl

Beta Pharma Inc

Biomar Microbial Technologies

Bionex Pharmaceuticals LLC

Biosergen AS

Cidara Therapeutics Inc

Dermala Inc

Gedea Biotech AB

General Biologicals Corp

Grupo Ferrer Internacional SA

Hsiri Therapeutics LLC

iCo Therapeutics Inc.

ImmunoClin Corp

Matinas BioPharma Holdings Inc

Nanomerics Ltd

Novabiotics Ltd

NovaDigm Therapeutics Inc

Novartis AG

Onxeo SA

Scynexis Inc

Sealife PHARMA GMBH

Viamet Pharmaceuticals Inc

Visterra Inc

Wellstat Vaccines LLC


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person